Posted by Michael Wonder on 01 Sep 2022
EMA CHMP adopts positive opinion recommending authorisation for the use of Moderna's Omicron targeting bivalent booster in the European Union
1 September 2022 - Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 sub-variants when compared with mRNA-1273.
Moderna today announced that the EMA's CHMP has adopted a positive opinion recommending conditional marketing authorisation for Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), the company's next generation bivalent vaccine candidate that contains mRNA-1273 and a vaccine candidate targeting the Omicron variant of concern (BA.1).
